Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Qinlock
Ripretinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. It works by targeting KIT and PDGFRA, receptor tyrosine kinases that are often mutated in GIST, leading to uncontrolled cell growth and proliferation.
Ripretinib is used to treat advanced gastrointestinal stromal tumors (GIST) in adults who have received prior treatment with 3 or more kinase inhibitors.
Outcome:
Increased ripretinib exposure
Mechanism:
Inhibition of CYP3A4-mediated metabolism
Outcome:
Increased midazolam exposure
Mechanism:
Inhibition of CYP3A4-mediated metabolism
Outcome:
No clinically significant interaction expected
Mechanism:
Different metabolic pathways
Most likely new formulation: Combination therapy with other targeted agents (2025, 70% confidence)
Based on clinical trial data and current usage trends, there is a high likelihood (80%) that ripretinib will remain a key treatment option for advanced GIST in the next 5 years.
Kinase Inhibitor, Antineoplastic Agent
Pyrimidin-2-amine derivative